99re热免费精品视频观看,久久久精品无码一区二区三区,国产精品白浆视频一区

AC-73

NMR下載 COA and HPLC MSDS下載
names：
AC-73
CAS號：
775294-71-8
MDL Number：
MF(分子式)： C21H21NO2 MW(分子量)： 319.4
EINECS: Reaxys Number:
Pubchem ID:2989791 Brand:BIOFOUNT

AC-73(775294-71-8)是 Cluster of Differentiation 147 (CD147) 的第一種特定的口服生物利用的抑制劑，可特異性破壞 CD147 的二聚化 (結(jié)合位點在 CD147 的 N 端 IgC2 域中包括 Glu64 和 Glu73)，從而抑制 CD147/ERK1/2/STAT3/MMP-2 途徑，并抑制肝癌細胞的運動和侵襲。AC-73 還是一種抗增殖藥，也是白血病細胞自噬的誘導(dǎo)劑。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM002116-10mg	10mg	99%	￥ 2140.00	￥ 2140.00		2-3天	- +	￥ 0.00
YZM002116-5mg	5mg	99%	￥ 1160.00	￥ 1160.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	AC-73(775294-71-8)
英文別名	AC-73,775294-71-8
CAS號	775294-71-8
Inchi	InChI=1S/C21H21NO2/c23-20-8-4-7-19(13-20)21(24)15-22-14-16-9-11-18(12-10-16)17-5-2-1-3-6-17/h1-13,21-24H,14-15H2
InchiKey	UECKKYNEEBRMIL-UHFFFAOYSA-N
分子式 Formula	C21H21NO2
分子量 Molecular Weight	319.4
溶解度Solubility
性狀	白色至灰白色固體粉末
儲藏條件 Storage conditions	storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

AC-73(CAS:775294-71-8)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說明	AC-73(cas:775294-71-8) 是Cluster of Differentiation 147 (CD147)的第一種特定的口服生物利用的抑制劑
Introduction	AC3 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disruptsCD147dimerization, thereby mainly suppressing theCD147/ERK1/2/STAT3/MMP pathways.
Application1	AC3 is also an antiroliferative drug and an inducer of autophagyin leukemic cells.
Application2	AC3 inhibits the motility and invasion of hepatocellular carcinoma cells.
Application3

IC₅₀ & Target	CD147
In Vitro	※ AC-73 (5-10 μM; 24 hours; SMMC-7721 and Huh-7 cells) treatment significantly decreases the migration ability of SMMC-7721 and Huh-7 cells in a dose-dependent manner and decreases the invasion of two HCC cells in a dose-dependent manner at 24 hours. AC-73 treatment reduces HCC metastases. There are no obvious effects on cell viability when two HCC cells are treated with AC-73 at a maximum concentration of 20 μM. The possible binding sites of AC-73 on CD147 included Glu64 and Glu73 in the N-terminal IgC2 domain, which two residues are located in the dimer interface of CD147. ※ AC-73 (5-10 μM; 24 hours; SMMC-7721 cells) treatment could significantly inhibit both MMP-2 and MMP-9 mRNA expression at the concentration of 10 μM, especially MMP-2, but no obvious effect on MMP-1, MMP-3, MMP-7, MMP-11 nor MMP-13. AC-73 could dose dependently reduce the expression of MMP-2 mRNA level and secretion of the protein level using RT-qPCR analysis and gelatin zymography experiments. ※ AC-73 (5-20 μM; 6 hours; SMMC-7721 cells) treatment dose-dependently suppresses the phosphorylation of ERK1/2 and STAT3.
	Cell Line:	SMMC-7721 cells
	Concentration:	5 μM or 10 μM
	Incubation Time:	24 hours
	Result:	Significantly inhibited both MMP-2 and MMP-9 mRNA expression at the concentration of 10 μM. Dose dependently reduced the expression of MMP-2 mRNA level and secretion of the protein level using RT-qPCR analysis and gelatin zymography experiments.
In Vivo	AC-73 (25-50 mg/kg; for 4 weeks; Male BALB/c nu/nu mice) treatment significantly decreases the incidence of metastatic foci in nude mice. AC-73 inhibits the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 is also reduced by AC-73. AC-73 could not inhibit tumor cell proliferation in vivo.
	Animal Model:	Male BALB/c nu/nu mice (4-6 weeks) with SMMC-7721 cells
	Dosage:	25 mg/kg, 50 mg/kg
	Administration:	Injected; daily; for 3 weeks
	Result:	Significantly decreased the incidence of metastatic foci in nude mice. Inhibited the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 was also reduced.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護